Wir nutzen Cookies auf unserer Website. Einige von ihnen sind essenziell, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Speichert die aktuelle PHP-Session.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Inhalte von Drittanbietern, bspw. Aktienwidgets, werden standardmäßig blockiert. Wenn Cookies von Drittanbietern akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Einwilligung mehr.
Wir verwenden zur Aktien-Chart-Anzeige den Anbieter TradingView. Dieser setzt weitere Cookies zur Analyse seiner Dienste ein.
Sie können unseren Newsletter abonnieren, dazu nutzen wir die Dienste von EQS. Dieser Anbieter setzt bei der Registrierung selbst verschiedene Cookies zur Nutzungsanalyse seiner Dienste ein.
In the third quarter of 2022, preliminary IFRS consolidated revenue rose by 1.2% to EUR 67.2 million compared to the second quarter of 2022 (EUR 66.4 million). The operating result (EBIT) of EUR 2.3 million in Q3/22 is almost at the level of the previous quarter (EUR 2.4 million). Compared to the previous year 2021, Group turnover for the first …
HAEMATO AG increased its revenue in the second quarter of 2022 by EUR 11.9 million compared to the first quarter of 2022 to EUR 66.4 million. The operating result (EBIT) increased from EUR 2.0 million to EUR 2.4 million in this period.
HAEMATO AG announces figures for the first quarter of 2022. According to these figures, the Group's consolidated revenue fell to EUR 54.6 million in the first quarter (previous year: EUR 73.9 million). EBITDA fell from EUR 2.8 million in the same quarter of the previous year to EUR 2.3 million. EBIT amounted to EUR 2.0 million in the first …
Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General …
Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit. HAEMATO remains on course for growth: according to preliminary IFRS financial statements, consolidated revenue in the 2021 financial year rose again by around 20% to EUR 285.0 million, after revenue growth of a good …
In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022. Mr. Attila Strauss has already been working as Chief Operating Officer at HAEMATO PHARM GmbH since 01.05.2021 and has also been Managing Director of the company since 01.10.2021.
Menu
